Phenelzine Shortage: What Providers and Prescribers Need to Know in 2026

Phenelzine (Nardil) remains one of the most effective pharmacological tools for treatment-resistant depression, atypical depression, panic disorder, and social anxiety disorder. Yet its persistent supply issues create a unique clinical challenge: your patients may face involuntary discontinuation of a medication they depend on for stability. This guide provides prescribers with the clinical and practical information needed to manage phenelzine supply disruptions safely.

Current Supply Status (2026)

In the United States, phenelzine is not under an active FDA-declared shortage as of 2026. ASHP last updated its bulletin in July 2021, noting Lupin's generic phenelzine sulfate 15 mg is available, with Pfizer's Nardil manufacturing delay resolved. However, manufacturers available on paper does not translate to medication available at pharmacies. Phenelzine's low dispensing volume means most pharmacies don't stock it on a routine basis — and a single wholesaler backorder can leave patients empty-handed.

Internationally, the picture is more concerning. Health Canada has listed phenelzine as a Tier 3 shortage with an unknown resupply date, attributing the problem to a global shortage of the active pharmaceutical ingredient. Prescribers with patients who may source medications internationally should be aware of this reality.

Why This Matters Clinically: The Withdrawal Risk

Unlike most antidepressants, phenelzine discontinuation carries a specific and serious risk: a withdrawal syndrome that typically begins 24–72 hours after abrupt cessation. Presentations range from vivid nightmares and insomnia to frank psychosis and seizures. This syndrome is distinct from depression relapse and requires active management.

Clinical pearls for managing phenelzine discontinuation:

Always taper rather than abrupt discontinuation. Gradual reduction over 2–4 weeks minimizes withdrawal risk.

Monitor closely if a rapid taper is unavoidable due to supply shortage.

Benzodiazepines may help manage acute withdrawal symptoms (anxiety, insomnia, agitation) but are not a substitute for phenelzine.

Educate patients to contact you immediately if they run low — before they are out.

MAOI-to-MAOI Transition Considerations

If phenelzine remains unavailable, some patients may be candidates for transition to another MAOI. Key considerations:

Tranylcypromine (Parnate): Most evidence-based MAOI alternative. Non-hydrazine structure means less weight gain, sexual dysfunction, and no pyridoxine deficiency risk. Requires 14-day washout from phenelzine. Start at 30 mg/day, titrate to 60 mg/day.

Isocarboxazid (Marplan): Hydrazine MAOI with similar profile to phenelzine. Approved up to 60 mg/day. Some meta-analyses suggest robust efficacy.

Selegiline transdermal (Emsam): Lower efficacy than oral MAOIs for TRD but better tolerated. At 6 mg/24hr, no dietary restrictions required. Useful for patients who struggle with the tyramine diet.

Note: No direct MAOI-to-MAOI crossover is recommended. All transitions require a complete washout period. Patients on phenelzine must wait at least 14 days before initiating a new MAOI.

Compounding as a Supply Bridge

In supply shortages, compounding pharmacies can sometimes prepare phenelzine from raw API if it's accessible. This option requires a compounding-specific prescription. Not all compounders will have API access during a global shortage, but it's worth contacting specialty compounding pharmacies in your region. Document the clinical rationale carefully.

Practical Steps for Prescribers

Proactively identify at-risk patients. Know which of your patients depend on phenelzine and contact them before shortage becomes a crisis.

Authorize 90-day supplies. Larger supplies reduce refill frequency and buffer against short-term availability gaps.

Specify both brand and generic on prescriptions. Allow substitution between Nardil (Pfizer) and generic phenelzine (Lupin, Greenstone). Pharmacies may have one but not the other.

Refer patients to medfinder. medfinder calls pharmacies near your patients to find which ones have phenelzine in stock — reducing the burden on your office staff.

Learn more about referring patients at medfinder for providers, or read our detailed provider's guide to helping patients find phenelzine in stock.